๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Zhejiang
Clinical trial register · China

Clinical Trials in Zhejiang, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Zhejiang

48 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Phase 2 Dose-Finding Study Evaluating the Efficacy and Safety of EDP167 in Adults With Mixed Dyslipidemia
NCT07799129Mixed Dyslipidemia
Eddingpharm (Zhuhai) Co., Ltd.
Phase 2
144
Harbin, Zhejiang
2026-11
Not yet open
Clinical Utility of Needle-Based Confocal Laser Endomicroscopy for Peripheral Pulmonary Lesions
NCT07827326Peripheral Pulmonary Lesions
First Affiliated Hospital of Ningbo University
Observational
100
Hefei, Zhejiang, Shanghai
2026-10-01
Not yet open
A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of RCZY690 in Advanced Solid Tumors
NCT07806175Advanced Malignant Solid Tumors
Rongchang Pharmaceuticals Co., Ltd.
Phase 1/2
486
Beijing, Hunan, Zhejiang, Shandong, Shanghai, Shanxi, Tianjin
2026-09-15
Not yet open
Clinical Trials Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian Cancer
NCT07779538Ovarian Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3
420
Beijing, Zhejiang, Yunnan
2026-09-01
Not yet open
18F-S2P PET Imaging in the Evaluation of Large Artery Atherosclerosis
NCT07815860Large-Artery Atherosclerosis (Embolus/Thrombosis)
First Affiliated Hospital of Zhejiang University
Not applicable
200
Zhejiang
2026-09
Recruiting
Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular Degeneration
NCT07776522Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
West China Hospital
Phase 2
50
Beijing, Jilin City, Chongqing, Shantou, Zhejiang, Harbin, Zhengzhou, Wuhan
2026-08-31
Not yet open
VBC117First-in-Human Trial of VBC117 in Participants With Advanced Malignant Solid Tumors
NCT07772934Advanced Solid Tumors
VelaVigo Bio Inc
Phase 1/2
260
Zhejiang, Zhengzhou, Changsha, Nanchang, Shengyang, Shanghai, Taiyuan
2026-08-24
Not yet open
Comparing Esketamine and Remazolam With Propofol for Breathing Safety in Pediatric Gastroscopy
NCT07748884Adverse Respiratory Events, Hypoxemia, Children, Gastroscopy
Second Affiliated Hospital of Wenzhou Medical University
Phase 4
120
Zhejiang
2026-08
Not yet open
Red Dichromatic Imaging for Improving Post-Biopsy Bronchoscopic Field Visibility
NCT07653945Bronchoscopic Biopsy, Airway Lesion, Biopsy-related Bleeding
First Affiliated Hospital of Ningbo University
Observational
206
Hefei, Zhejiang, Shanghai
2026-07-01
Recruiting
Phase III Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above
NCT07817108Varicella-zoster Virus
Suzhou Abogen Biosciences Co., Ltd.
Phase 3
18,000
Jinan, Nanning, Shijiazhuang, Zhejiang
2026-06-27
Recruiting
Safety, Pharmacokinetic (PK) Profile and Efficacy of Inpegsomatropin Injection in Adults With Growth Hormone Deficiency
NCT07551804Adult Growth Hormone Deficiency
Xiamen Amoytop Biotech Co., Ltd.
Phase 2
36
Beijing, Henan, Shanghai, Sichuan, Xiamen, Zhejiang
2026-06-10
Recruiting
Bone Management in Pregnancy Outcomes in Epilepsy
NCT07651709Epilepsy, Pregnant Woman, Bone Health
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Not applicable
80
Zhejiang
2026-06
Not yet open
Clinical Study of Chemogenetic Gene Therapy With AAV for Parkinson's Disease Using Stereotactic Surgery in the Subthalamic Nucleus
NCT07533591Parkinson's Disease (PD)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase EARLY_PHASE1
6
Zhejiang
2026-05
Not yet open
TMS for Improving Cognitive Function in Bipolar Disorder
NCT07414147Bipolar Disorder (BD), Cognitive Impairment
First Affiliated Hospital of Zhejiang University
Not applicable
88
Zhejiang
2026-03-01
Active, closed
Effect of Bagua Auriculotherapy on Pain in Patients Undergoing Hysteroscopy
NCT07512791Procedural Pain
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Not applicable
132
Zhejiang
2026-03-01
Recruiting
Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC
NCT07492342Resectable NSCLC, KRAS G12C Mutation, Stage IB-IIIA NSCLC, Neoadjuvant Therapy
Jianxing He
Phase 2
30
Beijing, Guangzhou, Zhejiang
2026-01-29
Not yet open
Biomechanical Study of Lever Positioning Manipulation on Scoliosis
NCT07325045Scoliosis
The Third Affiliated hospital of Zhejiang Chinese Medical University
Not applicable
30
Zhejiang
2026-01-10
Active, closed
A Study to Evaluate the PK Similarity of AK112 in Healthy Chinese Male Subjects
NCT07340476Healthy Male Subjects
Akeso
Phase 1
108
Zhejiang
2025-12-11
Active, closed
Construction of a Predictive Model for the Efficacy of Chemoprevention Combined With Targeted Therapy in Pancreatic Cancer
NCT07326150Pancreatic Cancer Resectable, Pancreatic Cancer Non-resectable
Zhejiang Cancer Hospital
Observational
70
Zhejiang
2025-12-08
Recruiting
JMT106 Injection in the Treatment of Advanced Solid Tumors
NCT07275073Advanced Solid Tumor, Lung Squamous Cell Carcinoma, Hepatocellular Carcinoma
Shanghai JMT-Bio Inc.
Phase 1
200
Zhejiang
2025-09-25
Recruiting
Low-Dose vs Standard-Dose Indomethacin for Preventing Post-ERCP Pancreatitis
NCT07088757Post-ERCP Pancreatitis
Changhai Hospital
Phase 4
1,366
Shanghai, Zhejiang
2025-09-15
Recruiting
Effect of Patient-Controlled Transcutaneous Electrical Acupoint Stimulation on Quality of Life in Chronic Cancer Pain
NCT07308951Quality of Life, Chronic Cancer Pain
The Third Affiliated hospital of Zhejiang Chinese Medical University
Not applicable
290
Zhejiang
2025-09-10
Recruiting
A Real-World Study of Fecal Transplants for Cancer Therapy Side Effects
NCT07319364Fecal Microbiota Transplantation (FMT), Gastrointestinal Neoplasms, Antineoplastic Agents, Drug-related Side Effects and Adverse Reactions
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1
90
Zhejiang
2025-09-01
Recruiting
Effect of Bright Light Therapy on Idiopathic Scoliosis
NCT07424703Idiopathic Scoliosis, Eveningness, Delayed Sleep Phase
Second Affiliated Hospital of Wenzhou Medical University
Not applicable
120
Zhejiang
2025-09-01
Recruiting
A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors
NCT07147348Advanced Solid Tumor
BioNTech SE
Phase 1/2
375
Beijing, Hefei, Henan, Hunan, Shandong, Shanghai, Sichuan, Zhejiang
2025-08-27
Recruiting
China Colorectal Cancer Screening Trial 1 (C-Cost1)
NCT07090291Colorectal Cancer, Advanced Adenoma
Zhejiang University
Not applicable
60,300
Guandong, Guangdong, Hebei, Nanjing, Shanghai, Sichuan, Zhejiang
2025-08-08
Recruiting
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
NCT07066657Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer
ArriVent BioPharma, Inc.
Phase 1
572
Beijing, Chongqing, Zhejiang, Heilongjiang, Zhengzhou, Wuhan, Changsha, Shandong
2025-07-25
Recruiting
Feasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tubes After Laparoscopic Distal Gastrectomy For Gastric Cancer
NCT07029269Gastric Adenocarcinoma, Laparoscopic Gastrectomy, Complications
Zuoyi Jiao
Phase 3
454
Beijing, Fuzhou, Lanzhou, Zhejiang, Xi'an
2025-06-16
Recruiting
Lecanemab for Early Onset Familial Alzheimer's Disease
NCT06883019Alzheimer Disease
RenJi Hospital
Observational
114
Beijing, Guangdong, Guizhou, Jiangsu, Shanghai, Sichuan, Tianjin, Zhejiang
2025-03-13
Recruiting
Effectiveness of Artificial IntelliGence-Driven Single-LEad Long-TerM Electrocardiograms MonItoring in Detecting New-Diagnosed Atrial FIbrillation
NCT06842147Atrial Fibrillation (AF)
Beijing Anzhen Hospital
Not applicable
15,360
Zhejiang
2025-03-01
Recruiting
Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002
NCT06832982Advanced Solid Tumors
Shanghai Pushi Medical Science Co. Ltd
Phase 1
66
Beijing, Fujian, Zhejiang, Heilongjiang, Shandong, Guangdong, Shenyang, Hebei
2025-02-24
Recruiting
Efficacy and Safety of Distamab Vedotin Combined With Carboplatin for Advanced Ovarian Cancer in the First Line Treatment
NCT07285941Ovarian Cancer, HER2
Zhejiang Cancer Hospital
Phase 2
20
Zhejiang
2025-01-04
Recruiting
89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study
NCT06750419Clear Cell Renal Cell Carcinoma
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3
82
Beijing, Hangzhou, Hubei, Shanghai, Suzhou, Tianjin, Wuxi, Zhejiang
2024-11-06
Recruiting
An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients With Advanced Solid Tumors
NCT06238401Advanced Solid Tumors
Hangzhou Adcoris Biopharmacy Co., Ltd
Phase 1
77
Beijing, Zhejiang, Shandong, Shanghai
2024-10-29
Active, closed
Establishment of a Predictive Model for Immunotherapy Response in Pancreatic Cancer
NCT07271823Pancreatic Cancer Non-resectable
Zhejiang Cancer Hospital
Observational
100
Zhejiang
2024-09-01
Recruiting
Peginterferon ฮฑ-2b Injection for Hydroxyurea Resistant or Intolerant ET
NCT06552429Essential Thrombocythemia
Xiamen Amoytop Biotech Co., Ltd.
Phase 2
27
Beijing, Fujian, Guangzhou, Harbin, Henan, Shanghai, Zhejiang
2024-08-29
Recruiting
A Study of JMT203 in Patients With Cancer Cachexia
NCT06868849Non Small Cell Lung Cancer, Pancreatic Cancer, Cancer Cachexia, Colorectal Cancer Cachexia
Shanghai JMT-Bio Inc.
Phase 1/2
307
Zhejiang
2024-05-15
Recruiting
Effect of Electroacupuncture Combined With Paclitaxel Clinical Efficacy of Patients With Recurrence of High-grade Glioma
NCT06330337Glioma
The Third Affiliated hospital of Zhejiang Chinese Medical University
Phase 3
58
Zhejiang
2024-04-01
Recruiting
A Multi-center RCT to Evaluate Subsegmental BTVA Treatment for Severe Emphysema
NCT06152107Severe Emphysema
Shanghai Chest Hospital
Not applicable
100
Zhengzhou, Beijing, Chengdu, Linyi, Nanchang, Shanghai, Shijiazhuang, Zhejiang
2024-01-01
Recruiting
Robot-assisted vs VATS for Thymoma
NCT06029621Thymoma
Shanghai Pulmonary Hospital, Shanghai, China
Not applicable
304
Shanghai, Zhejiang
2023-11-20
Active, closed
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy
NCT05949593Geographic Atrophy
Belite Bio, Inc
Phase 3
429
Beijing, Chengdu, Guandong, Zhejiang
2023-07-27
Recruiting
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
NCT05614739Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
Eli Lilly and Company
Phase 1
677
Beijing, Guangdong, Hangzhou, Shanghai, Tianjin, Xi'an, Zhejiang
2023-01-12
Active, closed
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04408638Diffuse Large B-cell Lymphoma
Hoffmann-La Roche
Phase 3
270
Beijing, Guangzhou, Harbin, Shanghai, Tianjin, Wuhan, Zhejiang, Zhengzhou
2021-02-23
Recruiting
Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer
NCT04518501Efficacy and Safety
Xing Xie
Phase 1/2
50
Zhejiang
2020-07-01
Active, closed
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
NCT04224493Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
Epizyme, Inc.
Phase 3
599
Fuzhou, Xiamen, Guiyang, Zhejiang, Shijiazhuang, Zhengzhou, Changsha, Changchun
2020-06-11
Active, closed
Evaluation of the Efficacy and Safety of the Application of BeGraft Peripheral Stent Graft System
NCT04023370Iliac Artery Stenosis
Bentley InnoMed GmbH
Not applicable
182
Beijing, Shanghai, Suzhou, Tianjin, Wuhan, Zhejiang
2019-09-19
Rows per page Showing 1–48 of 48
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/zhejiang

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 48 of those studies with a site in Zhejiang.

How many clinical trials are recruiting in Zhejiang?

29 of the 48 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 11 have not yet opened recruitment, 8 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Zhejiang), 48 studies
PhaseStudiesRecruitingShare
Not applicable12725%
Phase 38416.7%
Phase 17614.6%
Phase 27614.6%
Observational6212.5%
Phase 1/25310.4%
Phase 4214.2%
Phase EARLY_PHASE1102.1%

Most active sponsors

Lead sponsors with the most studies (Zhejiang)
Lead sponsorStudiesRecruiting
Zhejiang Cancer Hospital53
The Third Affiliated hospital of Zhejiang Chinese Medical University32
First Affiliated Hospital of Ningbo University20
First Affiliated Hospital of Zhejiang University20
Second Affiliated Hospital of Wenzhou Medical University21
Second Affiliated Hospital, Zhejiang University, School of Medicine21
Shanghai JMT-Bio Inc.22
The Fourth Affiliated Hospital of Zhejiang University School of Medicine21
Xiamen Amoytop Biotech Co., Ltd.22
Akeso10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.